Status:
COMPLETED
Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis
Lead Sponsor:
LEO Pharma
Collaborating Sponsors:
Bayer
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
Purpose of the study: One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until...
Detailed Description
The study has initially been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Intendis GmbH, a Bayer HealthCare company, is the sponsor of t...
Eligibility Criteria
Inclusion
- Acute 'Severe' or 'Very Severe' flare of atopic dermatitis; no minimum affected body surface
- History of moderate to severe form of atopic dermatitis for at least two years
Exclusion
- Pregnancy, breast feeding
- Known immune, hepatic, or renal insufficiency
- Acute herpes simplex or mollusca contagiosa infection
- Acute and severe impetigo contagiosa. A slight superinfection of eczema is no exclusion criterion
- Severe other viral, bacterial, or fungal skin infection (chicken pox, prominent tinea corporis)
- Acute infestations (e.g. head lice, scabies)
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00185510
Start Date
March 1 2005
End Date
June 1 2006
Last Update
June 9 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.